Fibrate
Gemfibrozil
Brand names: Lopid
Adult dose
Dose: 1.2g/day in 2 divided doses (max 1.5g/day)
Route: PO
Frequency: BD
Clinical pearls
- Severe hypertriglyceridaemia where fenofibrate not suitable; rarely used now
- Major drug-interaction risk: avoid with statins
Contraindications
- Severe hepatic/renal impairment
- Gallbladder disease
- Concurrent statins (rhabdomyolysis — avoid combination, particularly with simvastatin/atorvastatin/pravastatin)
- Concurrent repaglinide/dasabuvir
Side effects
- Myopathy/rhabdomyolysis
- GI upset
- Cholelithiasis
Interactions
- Statins — AVOID combination
- Repaglinide (severe hypoglycaemia)
- Warfarin (raised INR)
Monitoring
- Lipids
- LFTs
- CK if symptoms
Reference: BNF; NICE CG181; https://bnf.nice.org.uk/drugs/gemfibrozil/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines